TAZOBACTAM

DRUG5 trials

Sponsors

Hellenic Institute For The Study Of Sepsis, Assistance Publique Hopitaux De Paris, Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca, Merck Sharp & Dohme LLC, M.D. Anderson Cancer Center

Conditions

Bacterial PneumoniaInfectious diseasesOther Infectious DiseasesSevere infectionsantibiotic therapy in Sepsis

Phase 2

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

CompletedNCT03485950

M.D. Anderson Cancer CenterOther Infectious Diseases

Start: 2018-05-16End: 2022-02-16Updated: 2022-03-15

Phase 3

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

CompletedNCT02493764

Merck Sharp & Dohme LLCBacterial Pneumonia

Start: 2015-11-24End: 2019-04-03Updated: 2020-04-16

A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS PROCALCITONIN-GUIDANCE AND MOLECULAR-GUIDED DIAGNOSIS AS MAINSTAY FOR THERAPY OF SEVERE INFECTIONS (The MODIFY trial)

Active, not recruitingCTIS2022-502962-26-00

Hellenic Institute For The Study Of SepsisSevere infections

Start: 2023-09-14Target: 190Updated: 2025-11-03

BICCS - Beta-lactam Intermittent versus Continuous infusion and Combination antibiotic therapy in Sepsis

Not yet recruitingCTIS2024-516849-39-01

Assistance Publique Hopitaux De Parisantibiotic therapy in Sepsis

Target: 600Updated: 2025-12-02

Phase 4

Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile neutropenic Oncohaematological Paediatric patients (e-STOP 2)

Not yet recruitingCTIS2025-524264-38-00

Fundacio Hospital Universitari Vall D’Hebron Institut De RecercaInfectious diseases

Target: 136Updated: 2026-05-05

Related Papers

Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study.

2026-01-26

Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis

Open Forum Infectious Diseases2023-05-043 citations

A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies

Open Forum Infectious Diseases2022-02-1413 citations

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

Clinical and Translational Science2021-10-2730 citations

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Clinical Infectious Diseases2020-07-06211 citations